Literature DB >> 33452446

CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.

Ameera Alsadeq1, Denis M Schewe2, Lennart Lenk3, Michela Carlet4, Fotini Vogiatzi3, Lea Spory3, Dorothee Winterberg3, Antony Cousins5, Michaela Vossen-Gajcy3, Olta Ibruli3, Christian Vokuhl6, Gunnar Cario3, Omar El Ayoubi1, Lisa Kramer1, Matthias Ritgen7, Monika Brüggemann7, Robert Häsler8, Martin Schrappe3, Stephan Fuhrmann9, Christina Halsey5, Irmela Jeremias4,10,11, Elias Hobeika1, Hassan Jumaa1.   

Abstract

Central nervous system (CNS) involvement remains a challenge in the diagnosis and treatment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as Igα), a signaling component of the preB cell receptor (preBCR), to be associated with CNS-infiltration and -relapse in B-cell precursor (BCP)-ALL patients. Furthermore, we show that downregulation of CD79a hampers the engraftment of leukemia cells in different murine xenograft models, particularly in the CNS.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33452446      PMCID： PMC7810877          DOI： 10.1038/s42003-020-01591-z

Source DB:  PubMed          Journal:  Commun Biol        ISSN： 2399-3642


  25 in total

1.  Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.

Authors:  Fotini Vogiatzi; Dorothee Winterberg; Lennart Lenk; Swantje Buchmann; Gunnar Cario; Martin Schrappe; Matthias Peipp; Paulina Richter-Pechanska; Andreas E Kulozik; Jana Lentes; Anke K Bergmann; Thomas Valerius; Fabian-Simon Frielitz; Christian Kellner; Denis M Schewe
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

Review 2.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

3.  Leukaemia hijacks a neural mechanism to invade the central nervous system.

Authors:  Hisayuki Yao; Trevor T Price; Gaia Cantelli; Brandon Ngo; Matthew J Warner; Lindsey Olivere; Sarah M Ridge; Elizabeth M Jablonski; Joseph Therrien; Stacey Tannheimer; Chad M McCall; Anjen Chenn; Dorothy A Sipkins
Journal:  Nature       Date:  2018-07-18       Impact factor: 49.962

4.  Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor.

Authors:  Vera Münch; Luca Trentin; Julia Herzig; Salih Demir; Felix Seyfried; Johann M Kraus; Hans A Kestler; Rolf Köhler; Thomas F E Barth; Geertruy Te Kronnie; Klaus-Michael Debatin; Lüder H Meyer
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

5.  Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Authors:  M Pfeifer; B Zheng; T Erdmann; H Koeppen; R McCord; M Grau; A Staiger; A Chai; T Sandmann; H Madle; B Dörken; Y-W Chu; A I Chen; D Lebovic; G A Salles; M S Czuczman; M C Palanca-Wessels; O W Press; R Advani; F Morschhauser; B D Cheson; P Lenz; G Ott; A G Polson; K E Mundt; G Lenz
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

6.  Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1.

Authors:  S Jeha; D Pei; S C Raimondi; M Onciu; D Campana; C Cheng; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Howard; J R Downing; W E Evans; M V Relling; C-H Pui
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528

7.  Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.

Authors:  M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Authors:  S Köhrer; O Havranek; F Seyfried; C Hurtz; G P Coffey; E Kim; E Ten Hacken; U Jäger; K Vanura; S O'Brien; D A Thomas; H Kantarjian; D Ghosh; Z Wang; M Zhang; W Ma; H Jumaa; K-M Debatin; M Müschen; L H Meyer; R E Davis; J A Burger
Journal:  Leukemia       Date:  2016-02-05       Impact factor: 11.528

9.  Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.

Authors:  J J Peschon; P J Morrissey; K H Grabstein; F J Ramsdell; E Maraskovsky; B C Gliniak; L S Park; S F Ziegler; D E Williams; C B Ware; J D Meyer; B L Davison
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.

Authors:  Seyedmehdi Shojaee; Lai N Chan; Maike Buchner; Valeria Cazzaniga; Kadriye Nehir Cosgun; Huimin Geng; Yi Hua Qiu; Marcus Dühren von Minden; Thomas Ernst; Andreas Hochhaus; Giovanni Cazzaniga; Ari Melnick; Steven M Kornblau; Thomas G Graeber; Hong Wu; Hassan Jumaa; Markus Müschen
Journal:  Nat Med       Date:  2016-03-14       Impact factor: 53.440
View more
  3 in total

1.  Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.

Authors:  Sujeetha A Rajakumar; Ildiko Grandal; Mark D Minden; Johann K Hitzler; Cynthia J Guidos; Jayne S Danska
Journal:  Cell Rep Med       Date:  2021-12-21

2.  Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Lennart Lenk; Dorothee Winterberg; Fotini Vogiatzi; Anna Laqua; Lea Spory; Ahmad Mayar; Anna Dietterle; Gina Münch; Christian Vokuhl; Julia Richter; Andrew G Polson; Thomas Schüler; Ulf D Kahlert; Matthias Peipp; Thomas Valerius; Martin Schrappe; Gunnar Cario; Hassan Jumaa; Elias Hobeika; Monika Brüggemann; Ameera Alsadeq; Denis M Schewe
Journal:  Hemasphere       Date:  2022-07-15

Review 3.  Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche.

Authors:  Nitesh D Sharma; Esra'a Keewan; Ksenia Matlawska-Wasowska
Journal:  Front Cell Dev Biol       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.